144 related articles for article (PubMed ID: 34674982)
1. Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype.
Marcault C; Boissel N; Haferlach C; Loschi M; Raynaud S; Cluzeau T
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e199-e205. PubMed ID: 34674982
[TBL] [Abstract][Full Text] [Related]
2. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
Mosna F; Papayannidis C; Martinelli G; Di Bona E; Bonalumi A; Tecchio C; Candoni A; Capelli D; Piccin A; Forghieri F; Bigazzi C; Visani G; Zambello R; Zanatta L; Volpato F; Paolini S; Testoni N; Gherlinzoni F; Gottardi M
Am J Hematol; 2015 Jun; 90(6):515-23. PubMed ID: 25753065
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and cytogenetic features and their influencing factors of core binding factor acute myeloid leukemia].
Li W; Mi YC; Liu BC; Zhou CL; Lin D; Wang HJ; Liu XP; Li QH; Bian SG; Wang JX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Oct; 33(5):517-24. PubMed ID: 22338135
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.
Zhai Y; Wang Q; Ji L; Ren H; Dong Y; Yang F; Yin Y; Liang Z; Wang Q; Liu W; Mei Y; Zhang L; Li Y
Cancer Med; 2023 Dec; 12(24):21592-21604. PubMed ID: 38062912
[TBL] [Abstract][Full Text] [Related]
5. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
6. Impact of residual normal metaphases in core binding factor acute myeloid leukemia.
Medeiros BC; Othus M; Fang M; Appelbaum FR; Estey EH
Cancer; 2012 May; 118(9):2420-3. PubMed ID: 21928314
[TBL] [Abstract][Full Text] [Related]
7. [Genetic abnormalities in core binding factor acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
[TBL] [Abstract][Full Text] [Related]
8. Core binding factor acute myeloid leukemia.
Paschka P
Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
[TBL] [Abstract][Full Text] [Related]
9. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
Hoyos M; Nomdedeu JF; Esteve J; Duarte R; Ribera JM; Llorente A; Escoda L; Bueno J; Tormo M; Gallardo D; de Llano MPQ; Martí JM; Aventín A; Mangues R; Brunet S; Sierra J
Eur J Haematol; 2013 Sep; 91(3):209-218. PubMed ID: 23646898
[TBL] [Abstract][Full Text] [Related]
10. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22).
Lai YY; Qiu JY; Jiang B; Lu XJ; Huang XJ; Zhang Y; Liu YR; Shi HL; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):733-40. PubMed ID: 16277833
[TBL] [Abstract][Full Text] [Related]
12. Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications.
Panigrahi C; Tikare N; Das PK; Padhi S
BMJ Case Rep; 2023 Aug; 16(8):. PubMed ID: 37591621
[TBL] [Abstract][Full Text] [Related]
13. Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
Choi EJ; Lee JH; Kim H; Choi Y; Lee WS; Lee SM; Park JH; Park HS; Lee JH; Lee KH;
Int J Hematol; 2021 Jun; 113(6):851-860. PubMed ID: 33655416
[TBL] [Abstract][Full Text] [Related]
14. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
15. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Dombret H; Preudhomme C; Boissel N
Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
[TBL] [Abstract][Full Text] [Related]
16. Core binding factor acute myeloid leukemia (CBF-AML) in México: a single institution experience.
Ruiz-Delgado GJ; Macías-Gallardo J; Lutz-Presno J; Garcés-Eisele J; Hernández-Arizpe A; Montes-Montiel M; Ruiz-Argüelles GJ
Rev Invest Clin; 2011; 63(1):25-30. PubMed ID: 21574542
[TBL] [Abstract][Full Text] [Related]
17. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.
Duployez N; Willekens C; Marceau-Renaut A; Boudry-Labis E; Preudhomme C
Expert Rev Hematol; 2015 Feb; 8(1):43-56. PubMed ID: 25348871
[TBL] [Abstract][Full Text] [Related]
18. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.
Ustun C; Marcucci G
Curr Opin Hematol; 2015 Mar; 22(2):85-91. PubMed ID: 25635758
[TBL] [Abstract][Full Text] [Related]
19. [A multivariate model for predicting induction response and prognosis in core binding factor acute myeloid leukemia].
Wang B; Hua XY; Lin RR; Yang B; Wu W; He B; Zhang XW; Xing SS; Li HQ
Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):796-802. PubMed ID: 31665853
[No Abstract] [Full Text] [Related]
20. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn N; Terzer T; Sträng E; Dolnik A; Cocciardi S; Panina E; Corbacioglu A; Herzig J; Weber D; Schrade A; Götze K; Schröder T; Lübbert M; Wellnitz D; Koller E; Schlenk RF; Gaidzik VI; Paschka P; Rücker FG; Heuser M; Thol F; Ganser A; Benner A; Döhner H; Bullinger L; Döhner K
Blood Adv; 2020 Dec; 4(24):6342-6352. PubMed ID: 33351131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
